Influence of BCR-ABL Transcript Type on Outcome in Patients with Chronic-Phase Chronic Myeloid Leukemia Treated with Imatinib

Conclusions Patients with BCR-ABL transcripts e14a2 transcripts have higher rates of CCyR at 6 months and higher rates of optimal molecular response at 3 months when compared to e13a2 or to both transcripts, but no difference in 5-year overall, progression-free and event-free survival. There was a superior 10-year overall survival among patients with transcripts e13a2 compared to e14a2 (alone or coexpressed with e13a2). Teaser We evaluated 170 consecutive CML patients in chronic phase treated with imatinib in first line. There was a superior 10-year overall survival (OS) in patients with BCR-ABL transcripts e13a2 compared to e14a2 (alone or coexpressed with e13a2) (93% vs. 73%, P=0.03). High/intermediate Sokal scores and transcripts e14a3 and e14a3+e14a2 were independent factors for poor OS in a multivariate analysis.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research